@isanatashaa's weekly tirzepatide shots, fact-checked

What did @isanatashaa actually say?

Honestly? Almost nothing coherent. The transcript for this tirzepatide video is largely incoherent, jumping from vague promises about "working on the new video" to a rambling story about meeting friends, growing up in "a five-year-old world," and checking something called "Wideo Wiki." The only phrase with any medical adjacency is a brief mention of "a lot of scar tissue" while apparently looking at something on screen.

This appears to be either a severely garbled auto-transcription of Spanish-language audio, or a video that is mostly visual content with only minimal spoken commentary about tirzepatide itself. Given the Spanish hashtags like #perdidadepeso and #tirzepatide, the creator is almost certainly speaking Spanish and the transcript is a machine-translation disaster. There are no verifiable medical claims to fact-check in the English transcript provided.

Does the science back this up?

There is nothing specific here to evaluate against the literature. But since the video is tagged with tirzepatide and weight loss, it is worth addressing what the actual science says about this drug, so viewers who land on content like this have something real to stand on.

Tirzepatide is a dual GIP and GLP-1 receptor agonist approved by the FDA in 2022 for type 2 diabetes (Mounjaro) and in 2023 for chronic weight management (Zepbound). The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed that participants on the highest dose (15 mg weekly) lost an average of 20.9% of their body weight over 72 weeks, which is substantially more than what older GLP-1 drugs like semaglutide produced in comparable trials. That is a real finding. It does not mean tirzepatide works the same for everyone, and it does not mean weekly injections are simple or complication-free.

What did they get wrong (or right)?

Without a clear transcript, it is impossible to fact-check specific claims. What we can evaluate is the framing. The caption says "otra semana mas" which translates to "another week" with an injection emoji. That framing, a regular weekly injection update, is common in tirzepatide content and is not inherently misleading.

The one fragment worth noting is the mention of "a lot of scar tissue." If the creator is referencing injection-site scar tissue from repeated subcutaneous injections, that is a real and underreported issue with weekly GLP-1 and GIP/GLP-1 therapies. Rotating injection sites is standard clinical guidance for exactly this reason. If the transcript is capturing something real here, that is actually a useful thing to show an audience. But we cannot confirm that is what was said.

• No false disease-cure claims detected in transcript.
• No dangerous dosing advice detected.
• No comparison between compounded and brand-name tirzepatide detected.

What should you actually know?

If you found this video because you are researching tirzepatide for weight loss, here is what the evidence actually supports. Tirzepatide produces meaningful, clinically significant weight loss in people with obesity or overweight with at least one weight-related condition. The SURMOUNT-2 trial (Garvey et al., 2023, The Lancet) confirmed these results specifically in people with type 2 diabetes, showing 15.7% weight loss at the highest dose.

Weekly injections require proper technique and site rotation to avoid lipodystrophy and scar tissue buildup. Common side effects include nausea, vomiting, and diarrhea, especially when starting or increasing dose. These are not reasons to avoid the medication, but they are reasons to work with a licensed provider rather than following a TikTok schedule. Tirzepatide is a prescription drug. Compounded versions available through some telehealth platforms are not FDA-approved and are not equivalent to brand-name Zepbound or Mounjaro.

Bottom line on this video

This fact-check hit a wall because the transcript is almost certainly a failed auto-transcription of Spanish audio. There are no checkable medical claims in the English text. That is not the creator's fault, but it does mean this video contributes to a pattern of GLP-1 content that looks informative from the outside, weekly updates, injection footage, weight loss hashtags, but delivers little that a viewer can actually use to make a better health decision. The "scar tissue" mention, if accurate, is the one moment of potential real-world clinical value here.